EGFR and colorectal carcinoma: Characterizing the EGFR activating mutations via identifying autophosphorylation of EGFR via immunohistochemistry (IHC) can be done to establish which CRC patients with EGFR-mutated tumors may derive any benefit from EGFR-targeted therapeutics.